COVID-19 et vaccins à adénovirus : expérience française de suivi renforcé de pharmacovigilance

As part of the COVID-19 vaccination campaign, the National Agency for the Safety of Medicines and Health Products and all 31 regional pharmacovigilance centers were mobilized in an exceptional reinforced vaccine pharmacovigilance surveillance system. Concerning adenovirus vaccines, Vaxzévria® and Jc...

Descripción completa

Detalles Bibliográficos
Autores principales: Massy, Nathalie, Atzenhoffer, Marina, Boulay, Charlène, Pecquet, Pauline-Eva, Ledys, Fanny, Cracowski, Jean-Luc, Masmoudi, Kamel, Lepelley, Marion, Gras-Champel, Valérie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. 2023
Materias:
Pharmacovigilance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862661/
https://www.ncbi.nlm.nih.gov/pubmed/36759287
http://dx.doi.org/10.1016/j.therap.2023.01.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862661/
https://www.ncbi.nlm.nih.gov/pubmed/36759287
http://dx.doi.org/10.1016/j.therap.2023.01.005

Ejemplares similares